BioPharma Services >> News and Events >> Eurofins expands its leading footprint in biopharmaceutical products testing with the acquisition of Chemical Analysis in Australia

Eurofins expands its leading footprint in biopharmaceutical products testing with the acquisition of Chemical Analysis in Australia

Sidebar Image

15 March 2019

Eurofins Scientific, the world leader in biopharmaceutical products testing, is pleased to announce its latest acquisition in the biopharmaceutical products testing market in the Asia Pacific region with the acquisition of Chemical Analysis Pty Ltd. ("CA"), the leading independent analytical and cGMP Quality Control (QC) services provider for biopharmaceutical products in located in Melbourne, Australia.

Founded 13 years ago, Chemical Analysis has grown rapidly to become one of the top biopharmaceutical product testing providers in the domestic market, serving the biopharma industries. The company employs 40 staff across its 4 key divisions (Pharmaceutical, Chromatography, Microbiological & NMR testing) in the eastern suburbs of Melbourne.

The acquisition of Chemical Analysis will be complimentary to the existing capabilities in the region, joining Eurofins ams Laboratories Pty Ltd operating in Sydney. The company therefore presents an excellent geographical and operational fit for the Group. Chemical Analysis further expands the Eurofins global biopharma service offering, and will enable the Group to further leverage its existing client relationships in Europe and North America, and accelerate its expanding client reach in Asia Pacific.

In return, Chemical Analysis will benefit from access to the complete range of Eurofins’ portfolio of services as the global reference in biopharmaceutical testing, which will enable it to expand its service offering and its footprint in the biopharmaceutical and medical device markets, as well as in the nutraceutical market in the region.

Click here for a copy of this announcement.